Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study
Open Access
- 11 February 2021
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 13 (1) , 1-8
Abstract
Background: There is an unmet need for noninvasive markers specific for kidney transplant rejection. Such a marker may eventually overcome the need for a transplant biopsy. In this pilot study, the potential of circulating cell-free nucleosomes (CCFN) to serve as a biomarker for kidney transplant rejection was evaluated. Methods: Forty de novo kidney transplant recipients were prospectively followed as part of a randomized, controlled clinical trial. Total CCFN (H3) and CCFN with the histone modifications H3K36me3 and H3 citrulline were measured in patients at four fixed time points: before transplantation and on days 3–6, 30 and 180 after kidney transplantation. In addition, serum collected at times of transplant rejection (n = 14) was analyzed. CCFN were measured with a Nu.Q™ Assay kit (VolitionRx), an ELISA-based assay using antibodies directed against nucleosomes. Results: For total CCFN (H3), H3K36me3, and H3 citrulline, the same pattern was seen over time: Concentrations were elevated shortly after transplantation (day 3–6) followed by a decline reaching baseline (pre-transplantation) values at days 30 and 180. At times of acute rejection, the median concentration of total CCFN (H3) was significantly higher compared to the stable situation (day 30): 4309 (3435–5285) versus 2885 (1668–3923) ng/mL, p < 0.05, respectively. Total CCFN (H3) had an acceptable ability to discriminate rejection from no rejection (AUC-ROC = 0.73) with a negative predictive value of 92.9%. For both histone modifications (H3K36me3 and H3 citrulline), there was no significant difference between episodes of acute rejection and the stable situation (day 30). Conclusion: In this pilot study, total CCFN (H3) concentrations are increased at times of acute kidney transplant rejection. The high negative predictive value implies that whenever a patient experiences loss of renal transplant function and the total CCFN (H3) is not increased, causes other than acute rejection should be considered. Clinical implementation of total CCFN (H3) measurement may avoid unnecessary and potentially harmful kidney transplant biopsies.Keywords
Funding Information
- Nierstichting (No. 17OI03)
This publication has 29 references indexed in Scilit:
- Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and StrategiesFrontiers in Medicine, 2019
- Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New BiomarkersTherapeutic Drug Monitoring, 2018
- The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trialsAmerican Journal of Transplantation, 2017
- Precision Transplant Medicine: Biomarkers to the RescueJournal of the American Society of Nephrology, 2017
- A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney TransplantationTransplantation, 2017
- The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular PathologyAmerican Journal of Transplantation, 2017
- Complications of Ultrasound-Guided Renal Transplant BiopsiesAmerican Journal of Transplantation, 2016
- Circulating nucleosomes as epigenetic biomarkers in pancreatic cancerClinical Epigenetics, 2015
- Imperfect Gold Standards for Kidney Injury Biomarker EvaluationJournal of the American Society of Nephrology, 2012
- Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formationJournal of Cell Biology, 2009